Drug intelligence / Profile preview

MKK-RHP12

Development stage
Preclinical
Lead developer
MAXVAX Biotechnology
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

MKK-RHP12 is a 12-valent recombinant human papillomavirus (HPV) vaccine candidate currently under development by MAXVAX Biotechnology. The vaccine is engineered using recombinant protein technology to produce virus-like particles (VLPs) that mimic the structure of twelve different HPV serotypes. By targeting a broader range of HPV types than existing 4-valent or 9-valent vaccines, MKK-RHP12 aims to provide expanded protection against high-risk strains associated with cervical, vulvar, vaginal, and anal cancers, as well as low-risk strains responsible for genital warts. The project is currently in the preclinical stage, utilizing the company's proprietary adjuvant platforms to optimize the immune response and ensure long-term efficacy.

Other names
12-valent Recombinant HPV Vaccine12-valent Recombinant Human Papillomavirus Vaccine

Beyond the preview

Go deeper on MKK-RHP12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MKK-RHP12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call